Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Colorectal Neoplasms 3Neoplasms 2Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × galactomannan × Clear all
NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

NCT00054977 2012-03-12

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

Galectin Therapeutics Inc.

Phase 1 Completed
40 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡